$16.66
4.80% today
Nasdaq, Apr 03, 06:36 pm CET
ISIN
US9183851057
Symbol
VTVT
Sector
Industry

vTv Therapeutics, Inc. Class A Stock price

$17.50
-0.70 3.85% 1M
+3.40 24.11% 6M
+3.69 26.73% YTD
-8.05 31.51% 1Y
-7.80 30.84% 3Y
-54.10 75.56% 5Y
-418.10 95.98% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+1.10 6.71%
ISIN
US9183851057
Symbol
VTVT
Sector
Industry

Key metrics

Market capitalization $45.71m
Enterprise Value $11.23m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.01
P/S ratio (TTM) P/S ratio 44.81
P/B ratio (TTM) P/B ratio 3.75
Revenue (TTM) Revenue $1.02m
EBIT (operating result TTM) EBIT $-24.18m
Free Cash Flow (TTM) Free Cash Flow $-25.31m
Cash position $36.75m
EPS (TTM) EPS $-3.41
Short interest 3.33%
Show more

Is vTv Therapeutics, Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

vTv Therapeutics, Inc. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast vTv Therapeutics, Inc. Class A:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast vTv Therapeutics, Inc. Class A:

Buy
100%

Financial data from vTv Therapeutics, Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1.02 1.02
-
100%
- Direct Costs 0.09 0.09
0% 0%
9%
0.93 0.93
1,133% 1,133%
91%
- Selling and Administrative Expenses 14 14
15% 15%
1,329%
- Research and Development Expense 11 11
15% 15%
1,124%
-24 -24
5% 5%
-2,362%
- Depreciation and Amortization 0.09 0.09
0% 0%
9%
EBIT (Operating Income) EBIT -24 -24
5% 5%
-2,371%
Net Profit -18 -18
9% 9%
-1,810%

In millions USD.

Don't miss a Thing! We will send you all news about vTv Therapeutics, Inc. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

vTv Therapeutics, Inc. Class A Stock News

Neutral
GlobeNewsWire
14 days ago
Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin Lafontaine as Chief Commercial Officer HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focuse...
Neutral
GlobeNewsWire
17 days ago
Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall duration of the trial from 12 to 6 months HIGH POINT, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development ...
Neutral
PRNewsWire
4 months ago
WESTON, Fla. , Dec. 9, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Cantex's azeliragon for the treatment of brain metastasis from breast cancer.
More vTv Therapeutics, Inc. Class A News

Company Profile

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Head office United States
CEO Paul Sekhri
Employees 23
Founded 2015
Website www.vtvtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today